Patents Issued in June 1, 2010
  • Patent number: 7727522
    Abstract: The invention relates to retroviral vectors (known as lentiviral vectors), which are used to transfer genes into cells that are at cell cycle stage G0, to methods for their production and to the use thereof for transferring genes into mammalian cells. Said vectors are derived from SIVsmmPBj14 (simian immunodeficiency virus) of the sooty mangabey monkey, strain PBj 14.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: June 1, 2010
    Inventors: Klaus Cichutek, Michael Muehlebach, Matthias Schweizer
  • Patent number: 7727523
    Abstract: Methods are provided for suppressing the immune system response in recipients of transplanted organs, tissues or cells. An extracorporeal quantity of blood from the intended transplant recipient is treated to induce monocytes contained in the blood to differentiate and form dendritic cells. The maturation of the dendritic cells is truncated at a stage where the dendritic cells can inactivate T cell clones which would otherwise generate an undesired immune system response. The immature dendritic cells can be directly administered to the transplant recipient, or the dendritic cells can be co-incubated with the bone marrow or stem cell preparation, prior to transplantation, in order to suppress or eliminate anti-recipient donor T cells contaminating the bone marrow or stem cell preparation. The methods can be used to suppress graft versus host disease in recipients of transplanted bone marrow or stem cells, or to suppress rejection of transplanted organs or tissue.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: June 1, 2010
    Assignee: Yale University
    Inventors: Richard Leslie Edelson, Carole Berger, Michael Girardi
  • Patent number: 7727524
    Abstract: The present invention provides a liquid seasoning, which brings on a sufficient salty taste although it has a low sodium concentration, and which exhibits for example a pharmacological effect such as an antihypertensive effect at a high level. The present invention relates to a liquid seasoning, which contains the following components (A) to (D): (A) 3.55% or less by weight of sodium; (B) 0.5% to 4.2% by weight of potassium; (C) more than 2% by weight of an acidic amino acid and/or more than 1% by weight of a basic amino acid; and (D) 0.05% to 10% by weight of a food material having an antihypertensive effect.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: June 1, 2010
    Assignee: Kao Corporation
    Inventors: Shigemi Tsuchiya, Youko Seo, Jun Kohori, Ryuji Ochiai, Atsushi Suzuki
  • Patent number: 7727525
    Abstract: The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: June 1, 2010
    Assignees: City of Hope, The Regents of the University of California
    Inventors: Anna M. Wu, Tove Olafsen, Andrew A. Raubitschek
  • Patent number: 7727526
    Abstract: The present invention concerns the use of a PTHrP antagonist for preparing a pharmaceutical composition for treating renal cell carcinoma (RCC) in a mammal and in particular in a human subject. Advantageously, the invention is of particular interest for inhibiting or reducing tumour growth and/or metastasis formation in kidney cancer and its metastatic developments, in particular in the lung and the liver.
    Type: Grant
    Filed: July 4, 2003
    Date of Patent: June 1, 2010
    Assignees: Universite Louis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM), Hopitaux Universitaires de Strasbourg
    Inventors: Thierry Massfelder, Herve Lang, Eric Schordan, Jean-Jacques Helwig
  • Patent number: 7727527
    Abstract: The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: June 1, 2010
    Assignee: Genentech, Inc.
    Inventor: David L. Shelton
  • Patent number: 7727528
    Abstract: Labeled antibodies, antibody fragments or peptides binding to soluble cytokines or cytokine receptors are used to diagnose whether a patient has cancer or an autoimmune disease. In a preferred embodiment, a radiolabelled tag that is chemically bound to a peptide, antibody, or antibody fragment specific for sTNFR-1 and/or sTNFR2 is injected into a patient with a tumor, or suspected tumor, or with any disease associated with STNF-1/STNF-2. The patient is then imaged using standard nuclear imaging equipment to detect areas or sites of concentration of the radiolabel and/or receptor/inhibitor and/or antigen. By screening for cancer by the substances it produces, using an injected antibody to that substance with a tracer attached to it, one can detect cancer at a very early stage, potentially even microscopically.
    Type: Grant
    Filed: July 20, 2005
    Date of Patent: June 1, 2010
    Assignee: Early Detection, LLC
    Inventor: Deborah Kay Adcock
  • Patent number: 7727529
    Abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: June 1, 2010
    Assignee: General Antibodies and Biotechnologies S.R.L
    Inventor: Roberto Burioni
  • Patent number: 7727530
    Abstract: The present invention relates to a pharmaceutical composition comprising of proline or proline derivatives or their salts, esters, isomers, racemates, enantiomeres or prodrugs together with an anti-cancer ligand, preferably an antibody directed to a tumour antigen. The invention is also directed to the use of proline or proline derivatives or their salts, esters, isomers or prodrugs for the manufacture of a pharmaceutical composition for treating cancer and to a method of cancer treatment by administering said composition.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: June 1, 2010
    Inventor: Zoser B. Salama
  • Patent number: 7727531
    Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: June 1, 2010
    Assignee: Valorisation-Recherche, Societe En commandite
    Inventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
  • Patent number: 7727532
    Abstract: Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: June 1, 2010
    Assignees: University of Massachusetts, Centers for Disease Control and Prevention
    Inventors: William D. Thomas, Jr., Donna M. Ambrosino, Robert Mandell, Susan Sloan, Gregory J. Babcock, Charles Rupprecht
  • Patent number: 7727533
    Abstract: Described is a family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family is STEAP-1, which appears to be a type IIIa membrane protein. STEAP-1 is a 339 amino acid protein. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: June 1, 2010
    Assignee: Genentech, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas Saffran, Steven Chappell Mitchell
  • Patent number: 7727534
    Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: June 1, 2010
    Assignee: Oncolytics Biotech Inc.
    Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
  • Patent number: 7727535
    Abstract: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: June 1, 2010
    Assignee: Wyeth
    Inventors: Gray Shaw, Dianne Sako, Ravindra Kumar, Jin Xu
  • Patent number: 7727536
    Abstract: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: June 1, 2010
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Colin Watanabe, William I. Wood
  • Patent number: 7727537
    Abstract: A stabilizing composition that also enhances permeation is provided for the topical or transdermal administration of an active ingredient. The composition preferably comprises collagen, elastin, sphingoside and cerebroside. Also provided are pharmaceutical or cosmetic formulations comprising an effective amount of an active agent and the stabilizing composition as well as methods of administering active agents topically or transdermally.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: June 1, 2010
    Assignee: DPM Therapeutics Corp.
    Inventor: Pankaj Modi
  • Patent number: 7727538
    Abstract: A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the treatment of hypersecretion of mucus, which inhibits mucus secretion by inhibiting mucus secretion by mucus secreting cells, and/or inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: June 1, 2010
    Assignee: Syntaxin Ltd.
    Inventors: Conrad Padraig Quinn, Keith Alan Foster, John Chaddock
  • Patent number: 7727539
    Abstract: A bioresorbable composite of a non-crystalline calcium phosphate ceramic synthesized within an encapsulating microspheres of bioresorbable polymeric material for use in bone repair and replacement is provided. Also provides are methods for producing these composites as well as porous, 3-dimensional scaffold produced by sintering together microspheres of this bioresorbable composite.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: June 1, 2010
    Assignee: Drexel University
    Inventors: Cato T. Laurencin, Archel M. A. Ambrosio, Janmeet S. Sahota
  • Patent number: 7727540
    Abstract: Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, which is characterized in that said surface has been treated with at least one selected organic phosphonate compound or a pharmaceutically acceptable salt or ester or an amide thereof; process for producing said implants.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: June 1, 2010
    Assignees: Universite de Geneve, Ecole Polytechnique Federale de Lausanne
    Inventors: Pierre Descouts, Björn-Owe Aronsson, Michael Grätzel, Carine Viornery, Peter Péchy
  • Patent number: 7727541
    Abstract: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric regions, which in turn contain at least one block copolymer. The block copolymer includes (a) at least one high Tg (glass transition temperature) polymer block that contains at least one high Tg vinyl ether monomer and (b) at least one low Tg polymer block that contains at least one low Tg vinyl ether monomer.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: June 1, 2010
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Robert E. Richard, Marlene C. Schwarz, Mark Boden
  • Patent number: 7727542
    Abstract: A bioactive material is made using fibroin solutions and suspensions that can be used alone or as a composite with particles such as core/shell particles. The material is designed to support the constructions, repair, regeneration or augmentation of bone and other tissues of the body. The solutions and suspensions can be loaded with core/shell-type particles comprising inorganic core materials that are coated with biodegradable polymers with an outer coating of a calcium phosphate precursor. The fibroin solutions, suspensions, and composites can be injected to fill cavities or to replace missing tissue. After injection, the materials can produce a scaffold capable of promoting tissue regeneration while degrading. The degradation of the particles, when present, can generate additional porosity within the scaffold and release other compounds in a controlled manner to enhance growth and activation of the cells necessary for tissue repair.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: June 1, 2010
    Assignee: University of Connecticut
    Inventors: Anthony T. DiBenedetto, Samuel Jien-shek Huang, Claudio Migliaresi, Antonella Motta
  • Patent number: 7727543
    Abstract: A biodegradable carrier is produced for preservation and/or controlled delivery of biologically active agents where said biodegradable carrier is a silica xerogel which is made from water and silane by using acid or base as a catalyst, and biologically active agents in said biodegradable carrier are infecting and/or transfecting viruses. Silica xerogel material can be pharmaceutically acceptable and it can be used as a medicine.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: June 1, 2010
    Assignee: DelSiTech Oy
    Inventors: Mika Koskinen, Eija Säilynoja, Manja Ahola, Harry Jalonen, Jukka Salonen, Veli-Matti Kähäri
  • Patent number: 7727544
    Abstract: The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment and/or prevention of myopia. An activating energy source is utilized to photopolymerize or crosslink molecules in the sclera, thereby increasing the strength of the tissue. The individual is administered a crosslinking reagent or photopolymerizable molecule that becomes associated with the membrane, which is then precisely exposed to an energy source, such as light or ultrasound.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: June 1, 2010
    Assignees: The Regents of the University of California, California Institute of Technology
    Inventors: Daniel M. Schwartz, Chang Jun Yu, Robert H. Grubbs, Julia A. Kornfield, Scott E. Fraser, Matthew S. Mattson
  • Patent number: 7727545
    Abstract: A polymeric material having improved gas permeability comprises units of fluorinated dioxole. The polymeric material may further comprise units of a hydrophobic monomer, a hydrophilic monomer, or combinations thereof. Such a polymeric material is desirably used to produce medical devices, such as ophthalmic devices that provide increased comfort to a user.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: June 1, 2010
    Assignee: Bausch & Lomb Incorporated
    Inventors: Joseph C. Salamone, Derek A. Schorzman
  • Patent number: 7727546
    Abstract: Individualized responsive dosing dietary supplement systems, compositions, methods of dosing, and processes of producing the same, which allow a consumer to generate individualistic biological responses/effects. More specifically, a dietary supplement system for generating individualized biological conditions/responses which utilizes ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, and/or other nutrients in a bio-active delivery system which preferably avoids first pass metabolism, such that an individual may take multiple doses of the same or different dietary supplement based on varying desired biological response within each 24 hour period is also disclosed.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: June 1, 2010
    Assignee: Micro Nutrient, LLC
    Inventors: Ricky Dean Moneymaker, Larry Scott Klesman, Jon Scott Theus
  • Patent number: 7727547
    Abstract: A tissue-adhesive formulation consists of a naturally occurring or synthetic polymerisable and/or cross-linkable material in particulate form, the polymerisable and/or cross-linkable material being in admixture with particulate material comprising tissue-reactive functional groups. The formulation may be used in the preparation of a tissue-adhesive sheet, by applying the formulation to at least one side of a core of a naturally occurring or synthetic polymeric material.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: June 1, 2010
    Assignee: Tissuemed Limited
    Inventors: David Harry Fortune, Graeme Kettlewell, David John Mandley, Ian Thompson, Diane Cook
  • Patent number: 7727548
    Abstract: The present invention provides a quickly disintegrating tablet which has quick disintegrability and solubility in an oral cavity, and does not have uncomfortable tastes such as bitterness, has a small variation of a tablet physical property even in storage under a humidifying condition, and has substantially no change in a medicine content in the tablet and tablet appearance and which is superior in stability; and a manufacturing method of the tablet. That is, it provides: a quickly disintegrating tablet which is prepared by blending a medicine with a saccharide and polyvinyl alcohol, which has small variations of tablet weight, tablet hardness, tablet diameter and tablet thickness, and which is superior in medicine stability in the tablet; and a manufacturing method of the tablet.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: June 1, 2010
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yutaka Morita, Masanobu Yasui, Takayuki Ohwaki, Yuki Tsushima
  • Patent number: 7727549
    Abstract: Otic compositions are disclosed. The compositions contain an otic drug and a carrier comprising a low molecular weight compound. The compositions do not drain out of the ear after administration.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: June 1, 2010
    Assignee: Alcon, Inc.
    Inventor: Bhagwati P. Kabra
  • Patent number: 7727550
    Abstract: The present disclosure relates to a biologically active biomatrix composition. In one embodiment, the biomatrix composition is derived from human amnions. The biomatrix is termed HuBiogel™. The composition of HuBiogel™ closely mimics naturally occurring basement membrane compositions and is capable of supporting a wide variety of cell types in vitro and in vivo. The HuBiogel™ biomatrix disclosed comprises, in one embodiment, laminin, collagen I, and collagen IV, and may further comprise any combination of the following: entactin, tenascin, fibronectin and proteoglycans. The biomatrix composition is essentially free of endogenous growth factors and proteolytic enzymes. Also described are two- and three-dimensional culture systems and physiological/pathological model systems utilizing the HuBiogel™ compositions.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: June 1, 2010
    Assignee: The UAB Research Foundation
    Inventors: Gene P. Siegal, Raj Singh
  • Patent number: 7727551
    Abstract: The present invention relates to modified-release oral pharmaceutical compositions containing one or more active principles solubilized, suspended or embedded in a suitably formulated amphiphilicmatrix which, loaded in hydrophilic matrices, provides different release profiles.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: June 1, 2010
    Assignee: Farmatron Ltd.
    Inventor: Maria Gabriella Massironi
  • Patent number: 7727552
    Abstract: A composition of an oral medicine or an oral medicine which can prevent an unpleasant taste of the medicine is herein disclosed. It is granules, powders, syrups and the like which is prevented from an unpleasant taste, comprising a basic medicine having an unpleasant taste and an anionic polymer such as carrageenan.
    Type: Grant
    Filed: March 26, 1998
    Date of Patent: June 1, 2010
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Koji Ukai, Tsutomu Hrada, Yasuyuki Suzuki
  • Patent number: 7727553
    Abstract: The present invention provides oral preparations with good disintegration containing a slightly water-soluble active ingredient, which comprise a mixture of a solid formed product (e.g. a granule) and a second disintegrant wherein said solid formed product comprises a slightly water-soluble active ingredient, a first disintegrant and a water-soluble excipient which is formed by using a water-soluble polymer binder; or comprises a solid formed product prepared from a slightly water-soluble active ingredient, a disintegrant and a sugar alcohol by using a water-soluble polymer binder. When orally administered, these oral preparations exhibit excellent dissolution characteristics of the active ingredient in the digestive tract, and further, these preparations can show equivalent dissolution profile even at different amounts of the active ingredient, and thus enable the selection of the most suitable medicament for each patient, which makes these preparations highly useful in the clinical field.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: June 1, 2010
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventor: Kazuyuki Fujihara
  • Patent number: 7727554
    Abstract: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: June 1, 2010
    Assignee: Board of Regents of the University of Nebraska by and Behalf of the University of Nebraska Medical Center
    Inventors: Vinod D. Labhasetwar, Sanjeeb K. Sahoo, Maram K. Reddy
  • Patent number: 7727555
    Abstract: Particles and related methods are disclosed. In some embodiments, a method of making particles can include forming a stream of a mixture including first and second materials, exposing the stream to a vibration, and treating the stream to form particles. The vibration can have, for example, a sinusoidal, triangular, and/or sawtooth waveform.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: June 1, 2010
    Assignee: Boston Scientific SciMed, Inc.
    Inventors: Paul DiCarlo, Janel Lanphere, Thomas V. Casey, II, Marcia Buiser, Erin McKenna
  • Patent number: 7727556
    Abstract: A pharmaceutical composition having improved solubility comprising a hydrophobic drug or pharmaceutically acceptable salt thereof and a compound having at least one carboxylic acid moiety, wherein the molar ratio of the compound having at least one carboxylic acid moiety to the hydrophobic drug or pharmaceutically acceptable salt thereof is from about 0.1:1 to about 25:1. The pharmaceutical composition exhibits rapid dissolution upon contact with physiological solvents, such as water, saliva or gastrointestinal fluids.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: June 1, 2010
    Assignee: Sandoz AG
    Inventors: Gary Barbera, Chetan Chhabildas Doshi, Mahendra R Patel, Pablo Davila, Satishkumar Ambalal Patel
  • Patent number: 7727557
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: June 1, 2010
    Assignee: Purdue Pharma LP
    Inventor: Richard Sackler
  • Patent number: 7727558
    Abstract: Polymeric delivery agents, delivery agent compounds and compositions comprising them which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: June 1, 2010
    Assignees: Emisphere Technologies, Inc., Virginia Commonwealth University
    Inventors: Sam J. Milstein, Eugene N. Barantsevitch, Nai Fang Wang, Jun Liao, John Smart, Richard Conticello, Raphael Ottenbrite
  • Patent number: 7727559
    Abstract: Methods and compositions useful for neuronal protection in retinal cells in vitro and the protection of mammalian cells from reactive oxygen species in vivo are provided. Ultrafine nano-size cerium oxide particles, less than 10 nanometers in diameter, have been provided to decrease reactive oxygen species (ROS) in retina tissue that generates large amounts of ROS. These reactive oxygen species (ROS) are involved in light-induced retina degeneration and age-related macular degeneration (AMD). Cerium oxide nanoparticles have been used to promote the lifespan of retinal neurons and protect the neurons from apoptosis induced by hydrogen peroxide in vitro and in vivo. The neuronal protection in retinal cells is achieved by decreasing generation of intracellular reactive oxygen species (ROS). Thus, cerium oxide particles are used to promote the longevity of retinal neurons in vitro and mammalian cells in vivo.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: June 1, 2010
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: James F. McGinnis, Junping Chen, Lily Wong, Steve Sezate, Sudipta Seal, Swanand Patil
  • Patent number: 7727560
    Abstract: The present invention relates to a method of suppressing malignant conditions, including cancer with complications such like hepatitis and platelet disorder in bleeding, by administering a composition of an extract of Canavalia ensiformis. Also, the invention is nontoxic to the individual and for improving functions of kidney as well as of liver, especially when involved in cancer.
    Type: Grant
    Filed: May 18, 2004
    Date of Patent: June 1, 2010
    Inventor: Sou Yi Lu
  • Patent number: 7727561
    Abstract: This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: June 1, 2010
    Assignee: Pacific Arrow Limited
    Inventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
  • Patent number: 7727562
    Abstract: Liquid medicaments incorporate about 1.0-3.0% active benzoyl peroxide (BP) by weight in substantially fully solubilized form, while being substantially free of acetone and other harsh, dermatologically undesirable solvents. The novel compositions are produced by (a) creating an emulsion or slurry of BP in an emollient, topically acceptable ester, and (b) dissolving the emulsion or slurry in absolute alcohol. The medicaments may be used in the treatment of BP-responsive skin conditions in mammals, e.g., acne vulgaris or rosacea. The novel medicaments may be dispensed directly to the affected skin area through the use of an applicator device comprising a fluid reservoir associated with a foam applicator tip, or via a spray dispenser, atomizer or pump spray.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: June 1, 2010
    Inventor: Steven T. Blackman
  • Patent number: 7727563
    Abstract: One or more embodiments of the invention are directed to methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans. The methods comprise the step of administering to the patients a composition comprising a therapeutically effective amount of an extract from pomegranate.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: June 1, 2010
    Assignee: Pom Wonderful, LLC
    Inventor: Michael Aviram
  • Patent number: 7727564
    Abstract: The present invention relates to stable, palatable, freeze-dried, fruit-based dietary supplements. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit and Jucara fruit.
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: June 1, 2010
    Assignee: K2A LLC
    Inventors: Kenneth A. Murdock, Alexander G. Schauss
  • Patent number: 7727565
    Abstract: Some embodiments provide a chewing or bubble gum composition which includes a liquid fill composition and a gum region which includes a gum base surrounding the liquid fill which may include a modified release component, wherein the gum region includes a polyol composition including at least one polyol and having a water solubility of less than 72% by weight at 25° C. The composition may also include a coating region which surrounds the gum region.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: June 1, 2010
    Assignee: Cadbury Adams USA LLC
    Inventors: Bharat Jani, Kishor Kabse
  • Patent number: 7727566
    Abstract: The present invention is directed to an energy bar having a mean hedonic score for consumer acceptability of at least about 5.2. Preferably, the energy bar is either a grain based energy bar or a chewy energy bar.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: June 1, 2010
    Assignee: Mars, Incorporated
    Inventors: Edward L. Rapp, Jamie Troy, Jeannette Dido, Douglas Mann, Thomas Collins, Kevin Rabinovitch, Ralph Lee, Neil Willcocks, Robert Boushell, Ralph Jerome, Tiago O. Rodrigues, John M. Kaiser, Ivonne E. Nill
  • Patent number: 7727567
    Abstract: To establish the integrity of a product located in a container a given feature of the product in the container is determined by means of a first measurement method in which a first physical property of the product is ascertained, the given feature is additionally ascertained at least directly or by means of a second measurement method which is based on a second physical property which is different from the first physical property, and the values obtained by means of the two measurement methods of the given feature are compared. If the product is a drink in a bottle and if the given feature is the fill level, the first measurement method can consist of the fill level being measured by means of absorption of an X-ray beam, and the second measurement method can consist of the change effected by the bottle in the resonant frequency of a high-frequency oscillating circuit being measured.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: June 1, 2010
    Assignee: Heuft Systemtechnik GmbH
    Inventor: Bernhard Heuft
  • Patent number: 7727568
    Abstract: The invention relates to an antimicrobial composition comprising a mixture of at least 20 wt. % lactic acid or a derivative thereof and an inorganic acid selected from a nitrogen, sulfur, and phosphorous acid, and mixtures thereof for use in animal nutrition. In one of the embodiments the composition further comprises at least one other acid selected from acetic acid, fumaric acid, gluconic acid, (iso)butyric acid, sorbic acid, (iso)valeric acid, maleic acid, malic acid, capronic acid, benzoic acid, and citric acid. In a special embodiment the composition comprises lactic acid or polylactide, which is attached to a support.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: June 1, 2010
    Assignee: Purac Biochem B.V.
    Inventor: Anne Cazemier
  • Patent number: 7727569
    Abstract: It is intended to provide a procedure for, in the fractionation of vegetable butter, transesterified fat or oil, isomerized hydrogenated fat or oil, etc. without the use of solvents, obtaining high-concentration component G2U (defined below) by concentrating operation through reduction of the amount of liquid component residue in crystal portion. There is provided a method of dry fractionation of fat or oil characterized in that fat or oil (A) containing components G2U and GU2 is fractionated through crystallization/solid-liquid separation into crystal fraction of concentrated G2U (AF) and liquid fraction of concentrated GU2 (AL), subsequently this crystal fraction (AF) is mixed with liquid G2U-containing fat or oil (B) whose GU2 concentration is lower than that of the liquid fraction (AL) and thereafter the mixture is separated into crystal fraction (BF) and liquid fraction (BL).
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: June 1, 2010
    Assignee: Fuji Oil Company, Limited
    Inventors: Yuji Kuwabara, Nobuaki Kanai, Toshiaki Takahashi, Yoshihiro Yamanaka
  • Patent number: 7727570
    Abstract: A process for the preparation of a bake stable nut butter emulsion which comprises the following steps (a) selecting a sugar syrup solution and diluting it with water until it contains an amount of sugar solids which is in the range 55-80 wt. %, (b) heating the solution to a temperature in the range 40-100° C., (c) dispersing a starch into the heated solution until it contains 1-5 wt. % of dissolved starch, (d) dispersing an emulsifier into the heated solution until it contains 0.5-3 wt. % of dissolved emulsifier, (e) dispersing a gelling agent into the heated solution until it contains 0.2-1 wt. % of dissolved gelling agent, (f) cooling the heated solution into which the starch, emulsifier and gelling agent have been dispersed to a temperature which is in the range of 20-50° C.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: June 1, 2010
    Assignee: Unilever Bestfoods, North America, division of Conopco, Inc.
    Inventor: Arjan Johannes Louter
  • Patent number: 7727571
    Abstract: Antioxidant polymers of the present invention comprise repeat units that include one or both of Structural Formulas (I) and (II): wherein: R is —H or a substituted or unsubstituted alkyl, acyl or aryl group; Ring A is substituted with at least one tert-butyl group or substituted or unsubstituted n-alkoxycarbonyl group; Ring B is substituted with at least one —H and at least one tert-butyl group or substituted or unsubstituted n-alkoxycarbonyl group; Rings A and B are each optionally substituted with one or more groups selected from the group consisting of —OH, —NH, —SH, a substituted or unsubstituted alkyl or aryl group, and a substituted or unsubstituted alkoxycarbonyl group; n is an integer equal to or greater than 2; and p is an integer equal to or greater than 0. The invention also includes methods of using and preparing these polymers.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: June 1, 2010
    Assignees: University of Massachusetts Lowell, The United States of America as represented by the Secretary of the Army
    Inventors: Ashok L. Cholli, Vijayendra Kumar, Javant Kumar, Virinder Singh Parmar, Lynne Ann Samuelson, Ferdinando F. Bruno